Laidlaw & Co.
Laidlaw & Company (UK) Ltd. is a UK-incorporated, FINRA-registered investment bank and broker-dealer operating from New York, with research and banking centered on biotechnology, pharmaceuticals and medical devices. It takes its name from Laidlaw & Co., a New York firm dating to 1842.
Activity24M
RatingsPrice targetsKey figures
- Stocks covered
- 412M
- Actions
- 412M
- Ratings / Price targets
- 3 / 1
- Initiations
- 2
- Buy-rated
- 100%of 3 rated
- Median upside
- +164.3%
- On record
- Jan 2015 – Sep 2026
Overview
Laidlaw Capital Markets offers our clients alternatives to highly structured financings that often paralyze a company’s capital structure.
Laidlaw launched healthcare capital markets, research and banking initiatives in 2011 and added metals, mining and natural resources in 2012. Its capital markets group says it seeks long-term relationships with growth companies and draws on a network of institutional and retail investors.
The Laidlaw name descends from Heran & Lees, a New York commission merchant founded in 1842, which became Laidlaw & Co. in 1873 and joined the NYSE in 1878. Today's broker-dealer was incorporated in England in 1999 as Sands Brothers International Limited and renamed Laidlaw & Company (UK) Ltd. in 2004; it is owned by Laidlaw Holdings Ltd. Matthew Eitner and James Ahern joined in 2010 to build its healthcare investment banking platform.
Milestones
- 1842
Heran & Lees, origin of the Laidlaw name, founded
- 1873
Original firm renamed Laidlaw & Co.
- 1878
Laidlaw & Co. joins the New York Stock Exchange
- 1999
Sands Brothers International Limited incorporated in England
- 2004
Renamed Laidlaw & Company (UK) Ltd.
- 2011
Launches healthcare research and investment banking practice
Firm facts
- Legal name
- Laidlaw & Company (UK) Ltd.
- Type
- Boutique
- Founded
- 1999
- Headquarters
- New York, United States
- Parent
- Laidlaw Holdings Ltd
- Chief Executive Officer
- Matthew D. Eitner
- Rating scale
- Strong BuyBuyHoldSell12 months
- Also filed as
- Laidlaw
- Website
- laidlawltd.com
Research philosophy
Laidlaw's equity research focuses on emerging growth companies in biotechnology, pharmaceuticals and medical devices. The firm says its analysts use industry expertise and relationships to track trends affecting the companies they cover, and assess expected performance alongside investment risk.
Rating methodology
Stocks are rated Strong Buy, Buy, Hold or Sell relative to the analyst's sector universe over 12 months.
Coverage12M
Sectors
Most covered24M
| Stock | Rating | Target |
|---|---|---|
 AEON Biopharma, Inc.AEON | Buy | — |
 EyePoint Pharmaceuticals, Inc.EYPT | Buy | — |
 Kazia Therapeutics LimitedKZIA | — | $25 |
 NewcelX Ltd.NCEL | Buy | — |
 Soleno Therapeutics, Inc.SLNO | Buy | — |
 Viking Therapeutics, Inc.VKTX | — | $110 |
Most active analysts
- Yale Jen1 notesVKTX
Recent actions
| Date | Stock | Rating action | Rating | Target | Analyst |
|---|---|---|---|---|---|
| Sep 9 | AEON Biopharma, Inc.AEON | Initiate | Buy | ||
| Aug 17 | EyePoint Pharmaceuticals, Inc.EYPT | Reiterate | Buy | ||
| Jul 13 | NewcelX Ltd.NCEL | Initiate | Buy | ||
| Apr 15 | Kazia Therapeutics LimitedKZIA | Target | $25 | ||
| Mar 27, 2025 | Soleno Therapeutics, Inc.SLNO | Reiterate | Buy | ||
| Nov 4, 2024 | Viking Therapeutics, Inc.VKTX | Target | $110 | Yale Jen | |
| Mar 19, 2024 | ARArcturus Therapeutics Holdings Inc.ARCT | Target | $79 | Yale Jen | |
| Dec 22, 2023 | CICingulate Inc.CING | Downgrade | Buy →Hold | ||
| Aug 14, 2023 | TCAlaunos Therapeutics, Inc.TCRT | Downgrade | Buy →Hold | ||
| Jan 20, 2022 | CICingulate Inc.CING | Reiterate | Buy | ||
| Oct 18, 2021 |  Ionis Pharmaceuticals, Inc.IONS | Target | $68 | Yale Jen | |
| Dec 23, 2019 | Soleno Therapeutics, Inc.SLNO | Reiterate | Buy |